Novel drug development for amyotrophic lateral sclerosis

Area of Science:

• Neuroscience
• Pharmacology
• Drug Discovery

Background:

• Amyotrophic lateral sclerosis (ALS) is a key focus for pharmaceutical research due to its experimental tractability.
• Understanding ALS cell death mechanisms may inform treatments for other complex neurodegenerative diseases.

Purpose of the Study:

• To review current and emerging therapeutic strategies for ALS.
• To highlight the diverse mechanisms of action and drug targets being investigated in ALS drug development.

Main Methods:

• Analysis of compounds in various clinical trial phases (Phase I, III, and industrial trials).
• Review of preclinical discovery programs exploring novel drug targets and small molecule therapeutics.
• Examination of drug discovery processes, including high-throughput screening and lead compound optimization.

Main Results:

• Riluzole, an approved ALS drug, is being tested for Alzheimer's, Parkinson's, and Huntington's diseases.
• Numerous compounds in Phase III trials for ALS target glutamate antagonism, growth factors, GABA agonism, and calcium channels.
• Phase I and preclinical studies explore a wider range of mechanisms, including antioxidants, apoptosis modulators, and small molecules for CNS delivery.

Conclusions:

• ALS drug development involves a broad spectrum of therapeutic mechanisms and targets.
• The development of effective treatments for ALS and other neurodegenerative diseases relies on industry-academy collaborations.
• Small molecule therapeutics and novel targets like caspases and protein kinases are crucial for future ALS drug discovery.